RxDoctor Payments Data

Wendy Kays

Adult Health · Miami, FLNPI 1760932404

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 458 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Viiv Healthcare Company at 48.9% of the total. Among adult health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,893in general payments, 2019–2025

Across 458 payments — averaging $28.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$6K
  • Gilead$3K
  • Theratechnologies Inc.$1K
  • Johnson & Johnson$835
  • Merck$469
  • Lilly USA, LLC$301
  • plus $566 from 7 others
$826in research payments, 2019–2025

Across 8 payments — averaging $103.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Viiv Healthcare Company$826

What the payments were for

  • Travel & lodging$190%
  • Food & beverage$12,80399%
  • Education$711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,893 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala177$723,000
DovatoDolutegravir Sodium/Lamivudine67$199,692
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf27$163,447
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$44,277
JanuviaSitagliptin Phosphate23$24,529
Megestrol Acetate13$2,097
ValacyclovirValacyclovir Hcl19$1,025
Rosuvastatin Calcium51$876
Ventolin HfaAlbuterol Sulfate11$642
Diclofenac Sodium14$261
Atorvastatin Calcium28$248
Acyclovir15$248
Ibuprofen24$243
Omeprazole15$217
Albuterol Sulfate HfaAlbuterol Sulfate11$216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$3,316$767,278189 claims
Viiv Healthcare CompanyDovato$6,304$199,69267 claims
Janssen Products, LPSymtuza$178$163,44727 claims
MerckJanuvia$469$24,52923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.

Other adult health in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →